当前位置:首页 > 报告详情

CagriSema 与 BMI 和腰围身高比治疗目标的达成:REDEFINE 1.pdf

上传人: 表表 编号:1280006 2026-07-18 13页 217.08KB

1、Luca Busetto et al.Presented at the 33rd European Congress on Obesity(ECO),May 1215,2026;Istanbul,Trkiye.Scan QR code or visit the website below for:Science Hub linkshttps:/ and achievement of BMI and waist-to-height ratio treatment targets:REDEFINE 1Luca Busetto1,Cynthia Karenina Osorto Contreras2,

2、Mikkel Hovden Christensen2,Deborah Horn3,Carel W.le Roux4,5,Barbara McGowan6,Claire Prener Miller2,W.Timothy Garvey71Department of Medicine,University of Padova,Padova,Italy;2Novo Nordisk A/S,Sborg,Denmark;3Center for Obesity Medicine and Metabolic Performance,University of Texas McGovern Medical Sc

3、hool,Houston,TX,USA;4Diabetes Complications Research Centre,Conway Institute,University College Dublin,Dublin,Ireland;5Diabetes Research Centre,Ulster University,Coleraine,UK;6Guys and St.Thomas NHS Foundation Trust,London,UK;7University of Alabama at Birmingham,Birmingham,AL,USA.This study was fund

4、ed by Novo Nordisk A/S and is registered with ClinicalTrials.gov(NCT05567796).Medical writing support was provided by James Parkinson,PhD,CMPP,of OPEN Health Communications,and funded by Novo Nordisk A/S,in accordance with Good Publication Practice(GPP)guidelines(ismpp.org/gpp-2022).Previously prese

5、nted at the 43rd Annual Meeting of The Obesity Society)held at ObesityWeek,November 47,2025,Atlanta,GA,USA.AD04.03Luca Busetto et al.Presented at the 33rd European Congress on Obesity(ECO),May 1215,2026;Istanbul,Trkiye.2Presenter disclosureLuca Busetto reports the following:Luca Busetto declares rec

6、eiving speaker fees from Pronokal and Rhythm Pharmaceuticals;and received consulting fees from Amgen,Boehringer Ingelheim,Bruno Farmaceutici,Eli-Lilly,Novonordisk,Pfizer,Recordati,Regeneron,and Roche.Luca Busetto et al.Presented at the 33rd European Congress on Obesity(ECO),May 1215,2026;Istanbul,Tr

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
1. **研究目的**:评估REDEFINE 1试验中CagriSema 2.4 mg/2.4 mg对BMI<27 kg/m²和腰高比(WHtR)<0.53治疗目标的达标率及对心脏代谢参数的影响。 2. **核心数据**: - CagriSema组BMI<27 kg/m²达标率41.4%,显著高于司美格鲁肽(29.4%)、卡格列肽(22.5%)和安慰剂(13.4%)。 - WHtR<0.53达标率:CagriSema组36.0%,司美格鲁肽29.4%,卡格列肽22.1%,安慰剂16.4%。 - 达标者体重减轻更显著(如CagriSema组-29.3% vs 未达标者-18.8%)。 3. **心脏代谢改善**:达标者中,CagriSema组血糖、血脂、血压等参数正常化比例最高(如血糖正常化率98.9%)。 4. **结论**:CagriSema近1/3患者达成治疗目标,且显著改善心脏代谢指标。
**CagriSema效果如何?** **肥胖治疗新目标?** **体重达标后更健康?**
客服
商务合作
小程序
服务号
折叠